Although BAP1 down-regulation did not affect the drug sensitivity of antitumor agents used to treat GBC, we showed that BAP1 down-regulation attenuated the sensitivity to bortezomib, which is clinically applied to multiple myeloma and an inhibitor of proteasome that regulates the accumulation of the abnormal protein and lethal stress in cells [30]. The gene discussed is BAP1; the disease is plasma cell myeloma.